Azelaic Acid 5% | Clindamycin 2%

Applied topically to acne-affected areas of the face or body per prescriber direction:

• Cleanse and dry the affected skin thoroughly before application.
• Apply a thin, even layer to the acne-prone area; do not apply to unaffected skin unnecessarily.
• Avoid contact with eyes, mouth, nostrils, and mucous membranes.
• Wash hands before and after application.
• This preparation is for external use only; do not apply to broken skin or open wounds.

Dosing is prescriber-determined. General principles:

• Topical clindamycin 1–2% is typically applied once or twice daily to acne-affected areas.
• Azelaic acid's established twice-daily regimen is consistent with this frequency.
• Treatment courses of 8–12 weeks are standard; prescribers should reassess for topical antibiotic resistance risk with prolonged clindamycin monotherapy — combination with non-antibiotic agents (such as azelaic acid in this formulation) is consistent with AAD guidelines recommending antibiotic combinations to minimize resistance.
• Avoid indefinite antibiotic monotherapy; the prescriber will determine appropriate treatment duration and need for maintenance with non-antibiotic agents.

• Azelaic Acid: Inhibits bacterial protein synthesis in Cutibacterium acnes; reduces production of reactive oxygen species by activated neutrophils in follicular units; inhibits 5-alpha-reductase activity; and normalizes keratinocyte differentiation and microcomedo formation to reduce comedogenesis.
• Clindamycin Phosphate: Hydrolyzed by skin esterases to free clindamycin, which binds to the 23S rRNA of the 50S ribosomal subunit in susceptible organisms (including Cutibacterium acnes and Staphylococcus epidermidis), blocking peptide bond formation and inhibiting bacterial protein synthesis; primarily bacteriostatic at topical concentrations.

This dual-agent formulation is prescribed for the prescriber-directed management of inflammatory acne vulgaris, with synergistic antibacterial activity plus normalization of follicular keratinization. Clinical considerations:

• The AAD 2024 acne guidelines endorse combination antibiotic/non-antibiotic topical regimens to optimize efficacy and reduce the risk of antibiotic resistance; the azelaic acid component here serves as the non-antibiotic agent.
• Clindamycin resistance in Cutibacterium acnes is an increasing clinical concern; concurrent azelaic acid provides a resistance-independent mechanism and is consistent with AAD guidance to pair topical antibiotics with non-antibiotic agents.
• Azelaic acid at 5% is a lower compounded concentration compared with FDA-approved 15–20% formulations; clinical benefit at 5% is primarily antimicrobial and anti-inflammatory; comedolytic benefit increases at higher concentrations.
• Prescribers should assess response at 8–12 weeks; transition to non-antibiotic maintenance therapy as acne improves to reduce resistance pressure.
• Monitor for contact dermatitis, which may manifest as erythema, scaling, or pruritus at the application site.

Contraindications:

• Hypersensitivity to clindamycin, lincomycin, azelaic acid, or any formulation component.
• History of clindamycin-associated colitis or antibiotic-associated pseudomembranous colitis (systemic absorption from topical application is low but not zero).

Warnings & Precautions:

• Pseudomembranous colitis has been reported with systemic clindamycin; while topical absorption is minimal, it remains a theoretical risk — advise patients to report new-onset diarrhea.
• Avoid contact with eyes, nostrils, and mucous membranes.
• Clindamycin resistance may develop with prolonged use; do not use indefinitely without prescriber re-evaluation.
• Azelaic acid: expect transient stinging or burning, particularly on inflamed skin.

Drug Interactions:

• Topical clindamycin may antagonize erythromycin (do not use concurrently).
• Concurrent keratolytics (benzoyl peroxide, retinoids, salicylic acid) may increase irritation; use with prescriber guidance.

Common Side Effects: Erythema, dryness, and peeling at the application site; transient stinging (azelaic acid); rare allergic contact dermatitis; oily skin or folliculitis at the application site.

Store at controlled room temperature (15–25°C / 59–77°F). Protect from light, heat, and excessive humidity. Keep tightly closed. Do not freeze. Keep out of reach of children. Use by the beyond-use date (BUD) per USP <795> compounding standards. Discard if product changes color, consistency, or develops unusual odor.

Is this preparation FDA-approved?

No. This is a patient-specific, prescriber-directed 503A compounded preparation from Genesis Compounding. Commercial topical clindamycin and azelaic acid products exist separately; this specific combination formulation is not FDA-approved as a finished drug product.

Why combine clindamycin with azelaic acid rather than using clindamycin alone?

Using clindamycin alone long-term increases the risk of Cutibacterium acnes developing antibiotic resistance. Azelaic acid provides a non-antibiotic antimicrobial and anti-inflammatory mechanism that complements clindamycin, consistent with AAD guidance to always pair topical antibiotics with non-antibiotic agents to reduce resistance pressure.

How should I apply this gel/cream?

Apply a thin layer to thoroughly cleansed and dried acne-prone skin once or twice daily as directed by your prescriber. Avoid eyes, mouth, and mucous membranes. Wash hands before and after application.

What side effects should I watch for?

Transient stinging, burning, or mild erythema at the site is common, particularly from azelaic acid, and usually resolves within the first few weeks. Report new-onset diarrhea, severe skin reactions, or worsening symptoms to your prescriber promptly.

How long will I need to use this?

Your prescriber will determine treatment duration based on your response. A typical course is 8–12 weeks; long-term antibiotic use will be reassessed, and your prescriber may recommend transitioning to a non-antibiotic maintenance regimen as acne improves.